Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy

G Ndrepepa, A Kastrati - Journal of Clinical Medicine, 2023 - mdpi.com
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …

New and revisited approaches to preserving the reperfused myocardium

RA Kloner, DA Brown, M Csete, W Dai… - Nature reviews …, 2017 - nature.com
Early coronary artery reperfusion improves outcomes for patients with ST-segment elevation
myocardial infarction (STEMI), but morbidity and mortality after STEMI remain unacceptably …

Current modalities and mechanisms underlying cardioprotection by ischemic conditioning

JH Rosenberg, JH Werner, MJ Moulton… - Journal of cardiovascular …, 2018 - Springer
Ischemic preconditioning is a process which serves to mitigate reperfusion injury.
Preconditioning of the heart can be achieved through natural, pharmacological, and …

Remote ischemic pre-conditioning attenuates adverse cardiac remodeling and mortality following doxorubicin administration in mice

ZM Gertz, C Cain, D Kraskauskas, T Devarakonda… - Cardio Oncology, 2019 - jacc.org
Objectives Because of its multifaceted cardioprotective effects, remote ischemic pre-
conditioning (RIPC) was examined as a strategy to attenuate doxorubicin (DOX) …

Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial

AP Vanezis, JR Arnold, G Rodrigo, FY Lai, R Debiec… - Heart, 2018 - heart.bmj.com
Background Remote ischaemic conditioning (rIC) is a cardioprotective tool which has shown
promise in preclinical and clinical trials in the context of acute ischaemia. Repeated rIC post …

Human umbilical cord tissue-derived mesenchymal stromal cells as adjuvant therapy for myocardial infarction: a review of current evidence focusing on pre-clinical …

L Raposo, AP Lourenço, DS Nascimento, R Cerqueira… - Cytotherapy, 2021 - Elsevier
Although biologically appealing, the concept of tissue regeneration underlying first-and
second-generation cell therapies has failed to translate into consistent results in clinical …

Meta-analysis of randomized trials of intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction undergoing …

A Elbadawi, IY Elgendy, M Megaly, K Mahmoud… - The American Journal of …, 2017 - Elsevier
The efficacy and safety of glycoprotein IIb/IIIa inhibitors via intracoronary (IC) route versus
the intravenous (IV) route are not well known. We conducted this meta-analysis of …

Novel findings and therapeutic targets on cardioprotection of ischemia/reperfusion injury in STEMI

J Li, D Sun, Y Li - Current Pharmaceutical Design, 2019 - ingentaconnect.com
Acute ST-segment elevation myocardial infarction (STEMI) remains a leading cause of
morbidity and mortality around the world. A large number of STEMI patients after the …

Temporal trends and outcomes of hospitalizations with Prinzmetal angina: perspectives from a national database

A Elbadawi, IY Elgendy, SY Naqvi… - The American Journal of …, 2019 - Elsevier
Background Contemporary data regarding the temporal changes in prevalence and
outcomes of hospitalizations with Prinzmetal angina are limited. Methods We queried the …

Феномен коронарной микрососудистой обструкции (no-reflow) при проведении чрескожных коронарных вмешательств у пациентов с инфарктом миокарда

АА Фролов, ИГ Починка, БЕ Шахов… - Патология …, 2020 - cyberleninka.ru
Развитие феномена коронарной микрососудистой обструкции (noreflow) при
чрескожных коронарных вмешательствах у пациентов с инфарктом миокарда …